Evidence map›Paper›PMID 35008953›Full record

ArticleInternational journal of molecular sciences2022

Biodegradable Poly-ε-Caprolactone Scaffolds with ECFCs and iMSCs for Tissue-Engineered Heart Valves.

Georg Lutter, Thomas Puehler, Lukas Cyganek, Jette Seiler, Anita Rogler, Tanja Herberth, Philipp Knueppel, Stanislav N Gorb, Janarthanan Sathananthan, Stephanie Sellers and 3 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Georg LutterDepartment of Cardiovascular Surgery, University Hospital Schleswig-Holstein (UKSH), 24105 Kiel, Germany.
Thomas PuehlerDepartment of Cardiovascular Surgery, University Hospital Schleswig-Holstein (UKSH), 24105 Kiel, Germany.ORCID 0000-0002-4990-1892
Lukas CyganekStem Cell Unit, Clinic for Cardiology and Pneumology, University Medical Center Göttingen, 37075 Göttingen, Germany.ORCID 0000-0001-9120-1382
Jette SeilerDepartment of Cardiovascular Surgery, University Hospital Schleswig-Holstein (UKSH), 24105 Kiel, Germany.
Anita RoglerDepartment of Cardiovascular Surgery, University Hospital Schleswig-Holstein (UKSH), 24105 Kiel, Germany.
Tanja HerberthDepartment of Cardiovascular Surgery, University Hospital Schleswig-Holstein (UKSH), 24105 Kiel, Germany.
Philipp KnueppelDepartment of Cardiovascular Surgery, University Hospital Schleswig-Holstein (UKSH), 24105 Kiel, Germany.
Stanislav N GorbDepartment of Functional Morphology and Biomechanics, Zoological Institute, Christian-Albrechts-University of Kiel, 24105 Kiel, Germany.ORCID 0000-0001-9712-7953
Janarthanan SathananthanDepartment of Centre for Heart Valve Innovation, St Paul's Hospital, University of British Columbia, Vancouver, BC V6T 174, Canada.
Stephanie SellersDepartment of Centre for Heart Valve Innovation, St Paul's Hospital, University of British Columbia, Vancouver, BC V6T 174, Canada.
Oliver J MüllerGerman Centre for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, 20251 Hamburg, Germany.ORCID 0000-0001-8223-2638
Derk FrankGerman Centre for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, 20251 Hamburg, Germany.
Irma HabenDepartment of Cardiovascular Surgery, University Hospital Schleswig-Holstein (UKSH), 24105 Kiel, Germany.
University Hospital Schleswig-Holstein · DEUniversity of British Columbia · CAChristian-Albrechts-Universität zu Kiel · DEUniversitätsmedizin Göttingen · DE

Funding

German Centre for Cardiovascular Research 09/2021
6 · The paper itself

Abstract

Clinically used heart valve prostheses, despite their progress, are still associated with limitations. Biodegradable poly-ε-caprolactone (PCL) nanofiber scaffolds, as a matrix, were seeded with human endothelial colony-forming cells (ECFCs) and human induced-pluripotent stem cells-derived MSCs (iMSCs) for the generation of tissue-engineered heart valves. Cell adhesion, proliferation, and distribution, as well as the effects of coating PCL nanofibers, were analyzed by fluorescence microscopy and SEM. Mechanical properties of seeded PCL scaffolds were investigated under uniaxial loading. iPSCs were used to differentiate into iMSCs via mesoderm. The obtained iMSCs exhibited a comparable phenotype and surface marker expression to adult human MSCs and were capable of multilineage differentiation. EFCFs and MSCs showed good adhesion and distribution on PCL fibers, forming a closed cell cover. Coating of the fibers resulted in an increased cell number only at an early time point; from day 7 of colonization, there was no difference between cell numbers on coated and uncoated PCL fibers. The mechanical properties of PCL scaffolds under uniaxial loading were compared with native porcine pulmonary valve leaflets. The Young's modulus and mean elongation at F

Indexed as

Heart ValvesTissue EngineeringTissue ScaffoldsAnimalsBiopolymersCaproatesCell Culture TechniquesCell DifferentiationCells, CulturedEndothelial Progenitor CellsExtracellular MatrixHumansInduced Pluripotent Stem CellsLactonesMesenchymal Stem CellsNanofibersBiopolymersCaproatescaprolactoneLactonesbiodegradableECFCsheart valveiMSCsPCL nanofiberstissue engineering

Identifiers

PMID35008953
PMCPMC8745109
OpenAlexW4206278988

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.